OM Outset Medical, Inc.
FY2025 10-K
Outset Medical, Inc. (OM) filed its fiscal year 2025 10-K annual report with the SEC on Feb 13, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model not detailed; focus on corporate governance and compliance policies
- • No new products, services, or segments introduced or emphasized this year
Management Discussion & Analysis
- • Revenue $119.5M, up 5% YoY from $113.7M; product revenue $84.8M (+5%), service revenue $34.7M (+6%)
- • Gross margin 39.1% vs 33.9%, gross profit $46.8M, up 21%, driven by higher console and consumable margins
Risk Factors
- • FDA warning letter in 2023 and ongoing compliance risks with medical device regulations impacting Tablo production and approval processes
- • Dependence on Mexico manufacturing exposed to U.S. tariffs risk from Section 232 Trade Expansion Act investigation started September 2025
Financial SummaryXBRL
Revenue
$119M
Net Income
-$82M
Gross Margin
39.1%
Operating Margin
-55.8%
Net Margin
-68.3%
ROE
-64.3%
Total Assets
$264M
EPS (Diluted)
$-5.37
Operating Cash Flow
-$46M
Source: XBRL data from Outset Medical, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Outset Medical, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.